Finance News – Stem Cell
What is your interest today?
Bitcoin
Crypto
Btc
Stocks
Shares
Tariffs
Investors
Stock
Ceo
Stock Market
Crypto Assets
Ethereum
Cryptocurrency
Price
Markets
Xrp
Eth
Bse
Etf
Earnings
Ipo
Stablecoin
Investment
Blockchain
Revenue
Solana
Index
Trade
Sec
Inflation
Interest Rates
Token
Wall Street
Sensex
Coinbase
Treasury
Federal Reserve
Nasdaq
Traders
Profit
Nse
China
Bse Sensex
Nifty
Sp 500
Investor
Gold
Tesla
Company
Economy
Betting Markets
Japanese Bonds
Asset Sale
Oxyzo
Brand Divestments
Nuclear Fuel
Sanctions Package
Atg
Shelf Offering
Global Debt Markets
= 1024) { setSearchBy('title'); suggestionOpen = true; fetch() }"
@input.debounce.300ms="window.innerWidth >= 1024 && fetch()"
@keydown.enter.prevent="window.innerWidth >= 1024 && submitSearch()"
placeholder="Search finance news…"
class="flex-grow bg-transparent border-0 focus:ring-0 px-4 py-2 placeholder-gray-500 dark:placeholder-gray-400 text-gray-900 dark:text-gray-100 mr-2"
/>
Filter by:
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Sydney Morning Herald Biz • Jul 28, 2025
Strategic CEO hire to drive NeuroScientific stem cell therapy release
The appointment of Nathan Smith as CEO is expected to enhance NeuroScientific Biopharmaceuticals' leadership and support the upcoming launch of their stem cell therapy, potentially...
Read Full Article →
Sydney Morning Herald Biz • Jun 27, 2025
New dawn for NeuroScientific with stem cell acquisition
NeuroScientific Biopharmaceuticals has expanded its portfolio by acquiring Perth’s Isopogen for $5.1 million, signaling a strategic move into the emerging stem cell therapy sector.
Read Full Article →